Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.9
3.4
Journals
Current Oncology
Special Issues
Surgical Management of Patients with Hepatobiliary and Pancreatic Malignancies
share announcement

Surgical Management of Patients with Hepatobiliary and Pancreatic Malignancies

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Surgical Oncology".

Deadline for manuscript submissions: closed (31 March 2026) | Viewed by 3645

Special Issue Editors

Dr. Cameron E Gaskill

E-Mail Website
Guest Editor
Department of Surgery, Davis Medical Center, University of California, Sacramento, CA 95817, USA
Interests: cancer; cancer surgery; public health; global health; gastrointestinal cancers; hepatobiliary surgery; pancreas surgery; colorectal (colon); melanoma; liver; pancreas; stomach
Dr. Jessica E. Maxwell

E-Mail Website
Guest Editor
Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: clinical & surgical outcomes; molecular & immune characterization of GI NET

Special Issue Information

Dear Colleagues,

This Special Issue focuses on the surgical management of patients with hepatobiliary and pancreatic malignancies, addressing critical aspects such as surgical techniques, postoperative outcomes, and survival rates. It explores the latest advancements in surgical approaches for liver, bile duct, and pancreatic cancers, including innovations in minimally invasive surgery, liver transplantation, and complex resections. Additionally, this Special Issue highlights regional disparities in surgical practices and outcomes, examining how healthcare infrastructure, surgical expertise, and access to advanced treatments impact patient prognoses across different regions. It also delves into survival differences, with a focus on factors influencing long-term survival, recurrence rates, and the role of adjuvant therapies. By addressing these multifaceted topics, this Special Issue aims to provide a comprehensive overview of the current state of surgical management for hepatobiliary and pancreatic malignancies, offering insights into improving patient outcomes and reducing global disparities in care.

Dr. Cameron E Gaskill
Dr. Jessica E. Maxwell
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • surgical management
  • hepatobiliary malignancies
  • pancreatic malignancies
  • surgical techniques
  • postoperative outcomes
  • survival rates
  • regional disparities
  • minimally invasive surgery
  • long-term survival
  • adjuvant therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 458 KB  
Article
Primary Tumor Size and Tumor–Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor
by Jin Guo, Kever A. Lewis, Laura Prakash, Priya Bhosale, Ajaykumar Morani, Matthew H. G. Katz, Ching-Wei D. Tzeng, Naruhiko Ikoma, Rebecca Snyder, Michael P. Kim, Chandrikha Chandrasekharan, Arvind Dasari, James C. Yao, Jeffrey E. Lee, Jessica E. Maxwell and Daniel M. Halperin
Curr. Oncol. 2026, 33(2), 111; https://doi.org/10.3390/curroncol33020111 - 12 Feb 2026
Viewed by 516
Abstract
Capecitabine/temozolomide (CAPTEM) is an established regimen for patients with metastatic pancreatic neuroendocrine tumors (PanNET) that is being increasingly used for tumor volume reduction in patients with borderline anatomically resectable disease. We sought to understand the response of the primary tumor, defined as changes [...] Read more.
Capecitabine/temozolomide (CAPTEM) is an established regimen for patients with metastatic pancreatic neuroendocrine tumors (PanNET) that is being increasingly used for tumor volume reduction in patients with borderline anatomically resectable disease. We sought to understand the response of the primary tumor, defined as changes in the tumor–vascular interface (TVI). This is a retrospective, single-institution study of patients with locally advanced or metastatic PanNET treated with CAPTEM between 2010 and 2020. RECISTv1.1 measurements and TVI assessments of the primary tumor were performed on pre- and post-therapy images. Patients with locally advanced or metastatic PanNET at presentation (n = 47) were included. CAPTEM was given for a median of 11 cycles. The most common site of metastatic disease was the liver (n = 38). An objective radiographic response in the primary tumor was observed in 6.4% (95% CI 1.7–18.6%) with clinical benefit in 70.2% (95% CI 54.9–82.2%). TVI was modified from >180° to ≤180° in 16.2% (95% CI 6.0–45.5%). Paired analysis of patients pre- and post-CAPTEM did not demonstrate a statistically significant shift in TVI with treatment (p = 0.134). A total of four patients had a change from an unresectable primary tumor to an anatomically resectable tumor following CAPTEM. In patients with locally advanced or metastatic PanNET, treatment with CAPTEM is associated with low radiographic response rates and changes in TVI. The degree to which these changes may correlate with surgical resection rates or R0 resections is not known. Extending these investigations in a cohort of PanNET patients offered CAPTEM for neoadjuvant intent could be helpful to understand whether these phenomena persist in that context. Full article
(This article belongs to the Special Issue Surgical Management of Patients with Hepatobiliary and Pancreatic Malignancies)
►▼ Show Figures

Figure 1

15 pages, 4720 KB  
Article
Prognostic Value of the PET/CT-Derived Maximum Standardized Uptake Value Combined with the Neutrophil–Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Undergoing Hepatectomy
by Tianyi Zhou and Chaoliu Dai
Curr. Oncol. 2026, 33(1), 13; https://doi.org/10.3390/curroncol33010013 - 25 Dec 2025
Viewed by 507
Abstract
Background: We aimed to evaluate ability of a novel scoring system that combines fluorodeoxyglucose-uptake parameters and systemic inflammatory response indicators to predict hepatocellular carcinoma (HCC) prognosis. Methods: Clinical data were collected from patients with HCC who underwent hepatectomy at our hospital in 2014–2022. [...] Read more.
Background: We aimed to evaluate ability of a novel scoring system that combines fluorodeoxyglucose-uptake parameters and systemic inflammatory response indicators to predict hepatocellular carcinoma (HCC) prognosis. Methods: Clinical data were collected from patients with HCC who underwent hepatectomy at our hospital in 2014–2022. The tumor-to-liver ratio (TLR) was adopted as a positron emission tomography/computed tomography (PET/CT) standardized uptake value (SUV)-related indicator and calculated as the ratio of the SUVmax of tumor tissue to the SUVmean of normal liver tissue. The patients’ immune microenvironment reflected the NLR. Postoperative overall survival (OS)- and disease-free survival (DFS)-related independent prognostic factors were analyzed using Cox proportional hazards regression modeling. Results: Eighty-nine patients were included. TLR, NLR, and alpha-fetoprotein levels were independently associated with OS and DFS. The OS and DFS in the zero-point group were significantly longer than those in the one- and two-point groups. Time-dependent ROC curve analyses revealed area under the curve values of 0.830 and 0.752 for 5-year OS and DFS, respectively, for the scoring system, outperforming single evaluation indices. Conclusions: The proposed scoring system, which incorporates both TLR and NLR, simultaneously reflects metabolic tumor characteristics and the host’s immune microenvironment, enabling more accurate patients with early to intermediate-stage HCC undergoing hepatectomy classification and better prognostic evaluation. Full article
(This article belongs to the Special Issue Surgical Management of Patients with Hepatobiliary and Pancreatic Malignancies)
►▼ Show Figures

Figure 1

10 pages, 474 KB  
Article
Surgical and Oncological Outcomes of Minimally Invasive Left Pancreatectomy for Pancreatic Cancer: Robotic vs. Laparoscopic Approach
by Matteo De Pastena, Gabriella Lionetto, Salvatore Paiella, Martina Maruccio, Federico Faustini, Elisa Venturini, Antonio Pea, Fabio Casciani, Giuseppe Malleo and Alessandro Esposito
Curr. Oncol. 2025, 32(7), 376; https://doi.org/10.3390/curroncol32070376 - 28 Jun 2025
Viewed by 1913
Abstract
Objective: This study compares the surgical and oncological outcomes of minimally invasive robotic (RLP) and laparoscopic (LLP) left pancreatectomy in pancreatic cancer (PC) patients. Methods: Data from patients who underwent minimally invasive left pancreatectomy between 2013 and 2023 were analyzed. Two groups were [...] Read more.
Objective: This study compares the surgical and oncological outcomes of minimally invasive robotic (RLP) and laparoscopic (LLP) left pancreatectomy in pancreatic cancer (PC) patients. Methods: Data from patients who underwent minimally invasive left pancreatectomy between 2013 and 2023 were analyzed. Two groups were identified: RLP and LLP. Perioperative outcomes were compared, including operative time, blood loss, conversion rate, and postoperative complications. Oncological outcomes included margin status, lymph node retrieval, lymph node status, overall survival (OS), and disease-free survival (DFS). Results: Fifty-four patients were divided into the LLP (n = 39) and RLP (n = 15) groups. The median operative time was shorter for LLP than RLP [260 min vs. 366 min, p = 0.007]. Blood loss and conversion rates were comparable (p > 0.05). In the LLP group, significantly more lymph nodes were harvested (29 vs. 19, p = 0.05), and a higher percentage of positive lymph nodes was noted (72% vs. 40%, p = 0.033). No significant difference was found in the R0 resection status (82% vs. 73%, p = 0.358). After a median follow-up of 26 months, OS (23 months vs. 34 months, p = 0.812) and DFS (17 months vs. 16 months, p = 0.635) were similar. Conclusion: RLP provides outcomes identical to LLP in treating body–tail pancreatic cancer, with further studies needed to confirm its long-term oncological efficacy. Full article
(This article belongs to the Special Issue Surgical Management of Patients with Hepatobiliary and Pancreatic Malignancies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop